GHENT, BELGIUM--(Marketwire - December 13, 2011) - Ablynx [Euronext Brussels: ABLX] today
announced that it has initiated a Phase I study in healthy volunteers with
0171, the first Nanobody in clinical development to be delivered by
ALX-0171 is being developed for the treatment of respiratory syncytial
The Phase I study is a single-centre, randomised, placebo-controlled trial
will investigate the safety, tolerability and PK profile of ALX-0171 in
volunteers. The study will include a single ascending dose part with six
levels, which is expected to recruit 44 subjects, followed by a multiple
part that is expected to recruit 16 subjects. Results of the
anticipated during the second half of 2012.
Dr Edwin Moses, CEO and Chairman at Ablynx, commented: "We believe there
high unmet need for a therapeutic treatment of RSV infection. ALX-0171
first Nanobody to enter clinical development that is administered
inhalation rather than injection. It has the potential to become a
class therapeutic for RSV infections. This alternative route of
in an acute disease setting is a good example of the competitive
and advantages our Nanobody technology platform can bring. We are
forward to seeing the results of this first-in-man trial, which are
during the third quarter of 2012."
RSV is a respiratory virus that infects the lungs and respiratory tract.
healthy people recover from an RSV infection within one or two weeks.
the infection can be much more severe in immune-compromised
elderly, infants with cardio-pulmonary disease and premature babies. RSV
most common cause of bronchiolitis (inflammation of the
smallest air passages of the lungs) and pneumonia in children younger
year old, and is increasingly being recognised as an important
respiratory illness in the elderly. Today, there are no widely
established antiviral agents available for the treatment of RSV.
infants can be protected with a prophylactic drug that is used to
against RSV infections. ALX-0171 has the potential to become a first-in-
therapeutic for the treatment of RSV and may address an even larger
population beyond high-risk infants in the therapeutic setting.
Complete version of the press release:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.